Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst [Seeking Alpha]
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: Seeking Alpha
EDG-7500 demonstrated strong tolerability and no clinically meaningful LVEF reductions, potentially differentiating it from cardiac myosin inhibitors for HCM treatment. Key 2026 catalysts include phase 2 CIRRUS-HCM efficacy data in Q2 2026 and potential phase 3 initiation for EDG-7500 in Q4 2026, targeting both oHCM and nHCM patients. EWTX is also advancing Sevasemten for BMD and DMD, with pivotal data and regulatory milestones expected in late 2026, supported by recent capital raises. Volodymyr Kalyniuk/iStock via Getty Images The last time I spoke about Edgewise Therapeutics, Inc. ( EWTX ), it was in a Seeking Alpha article entitled "Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On." With respect to this article, I went over the More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to sub
Show less
Read more
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- A Look At Edgewise Therapeutics (EWTX) Valuation After J P Morgan Clinical Pipeline Update [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026PR Newswire
- Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026PR Newswire
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR Newswire
- This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits [Yahoo! Finance]Yahoo! Finance
EWTX
Earnings
- 11/6/25 - Beat
EWTX
Sec Filings
- 1/15/26 - Form 144
- 1/5/26 - Form 4
- 12/29/25 - Form 144
- EWTX's page on the SEC website